ChemicalBook >제품 카탈로그 >API>신경계 약물>항 파킨슨 약>Bromocriptine

Bromocriptine

Bromocriptine 구조식 이미지

카스 번호:: 25614-03-3

상품명:: Bromocriptine

동의어(영문):: Parlodel;bromoergocryptine;BROMOCRITINE;bromocryptine;2-bromo-ergocryptin;Kripton;SAN 15-754;bromocriptin;,6’,18-trione;BROMOCRIPTINE

CBNumber:: CB6136426

분자식:: C32H40BrN5O5

포뮬러 무게:: 654.59

MOL 파일:: 25614-03-3.mol

속성

안전

용도

공급 업체 69

Bromocriptine 속성

녹는점: 215-218° (dec)

알파: D20 -195° (c = 1 in methylene chloride)

끓는 점: 891.3±65.0 °C(Predicted)

밀도: 1.2734 (rough estimate)

굴절률: 1.6400 (estimate)

산도 계수 (pKa): pKa 4.90±0.05(80% MCS t = RT) (Uncertain)

수용성: 2.07mg/L(온도 미공개)

CAS 데이터베이스: 25614-03-3(CAS DataBase Reference)

안전

위험 및 안전 성명
위험 및 사전주의 사항 (GHS)

독성	An ergot alkaloid derivative that exhibits potent dopamine agonist properties, particularly at D2 dopamine receptors. Bromocriptine, like dopamine, inhibits prolactin release from the pituitary and so is used in endocrine disorders, such as hyperprolactinemia. It is also used in the treatment of Parkinson’s disease. A large “first-pass” effect is seen with bromocriptine, and peak concentrations occur about 1.5-3 h after ingestion, with a half-life of about 3 h. Nausea, vomiting, and orthostatic hypotension are among the acute adverse effects. Long-term use has been associated with dyskinesias, constipation, psychoses, digital spasm, and erythromelalgia. The LD50 in rabbits exceeds 1 g/kg, p.o., and 12 mg/kg, i.v.

그림문자(GHS):

신호 어:

Warning

유해·위험 문구:

암호	유해·위험 문구	위험 등급	범주	신호 어	P- 코드
H302	삼키면 유해함	급성 독성 물질 - 경구	구분 4	경고	P264, P270, P301+P312, P330, P501
H361	태아 또는 생식능력에 손상을 일으킬 것으로 의심됨	생식독성 물질	구분 2	경고	P201, P202, P281, P308+P313, P405,P501
H362	모유를 먹는 아이에게 유해할 수 있음	생식독성 물질,수유 또는 수유기에 미치는 영향	추가 카테고리		P201, P260, P263, P264, P270,P308+P313

예방조치문구:

P201	사용 전 취급 설명서를 확보하시오.
P202	모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.
P260	분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P263	임신·수유 기간에는 접촉하지 마시오.
P264	취급 후에는 손을 철저히 씻으시오.
P264	취급 후에는 손을 철저히 씻으시오.
P270	이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P281	요구되는 개인 보호구를 착용하시오
P301+P312	삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P308+P313	노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
P330	입을 씻어내시오.
P405	밀봉하여 저장하시오.
P501	...에 내용물 / 용기를 폐기 하시오.

Bromocriptine C화학적 특성, 용도, 생산

화학적 성질

Crystals.

용도

Bromocriptine, a dopaminomimetic that is a dopamine D2 receptor agonist, possesses expressed antiparkinsonian activity. It is used for treating all phases of idiopathic and postencephalic Parkinsonism.

정의

An semisynthetic ergotamine alkaloid derivative and powerful dopamine D2 agonist. It inhibits prolactin secretion and release from the pituitary and retards tumor growth.

World Health Organization (WHO)

Bromocriptine, a semisynthetic ergot alkaloid derivative and prolactin inhibitor was introduced into medicine in 1976. It is used in the prevention of lactation, but because of the risk of rebound effect and since only 10% of women benefit therapeutically from such intervention, the United States Food and Drug Administration has requested manufacturers to no longer indicate preparations containing bromocriptine for this purpose. The World Health Organization is not aware of similar action having been taken elsewhere.

위험도

Poison; teratogen; developmental abnor- malities of the respiratory system,musculoskeletal system, rogenital system, craniofacial area, and body wall; teratogen; mutagen; questionable car- cinogen; tumorigen; causes nausea, vomiting, orthostatic hypotension; constipation, dyskinesias, psychoses, digital spasm, erythromelalgia.

Mechanism of action

Bromocriptine is absorbed after oral administration, but approximately 90% of a dose undergoes extensive first-pass hepatic metabolism, with the remainder hydrolyzed in the liver to inactive metabolites that are eliminated mostly in the bile. The half-life is relatively short (~3 hours).

Clinical Use

Bromocriptine is an ergot peptide derivative that is a partial agonist at D1-type and a full agonist at D2-type postsynaptic dopamine receptors, usually given in combination with levodopa therapy. It was the first direct dopamine receptor agonist used in treatment of Parkinson's disease after its development as an inhibitor of prolactin release (via activation of anterior pituitary D2 receptors). At low doses (typically 1–5 mg/day), bromocriptine is an effective prolactin inhibitor, and at higher doses (typically 10–20 mg/day), the antiparkinsonism and mood-elevating effects of bromocriptine become apparent.

부작용

Bromocriptine has a number of undesirable side effects, even causing mental disturbances in long-term use.

Bromocriptine 준비 용품 및 원자재

원자재

Imine 브로모숙신산 알파-에르고크립틴 N-브로모숙신산이미드

준비 용품

Bromocriptine 공급 업체

글로벌( 69)공급 업체

공급자	전화	이메일	국가	제품 수	이점
Hebei Yanxi Chemical Co., Ltd.	+8617531190177	peter@yan-xi.com	China	6011	58
hebei hongtan Biotechnology Co., Ltd	+86-86-1913198-3935 +8617331935328	sales03@chemcn.cn	China	971	58
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29914	58
Shanghai Longyu Biotechnology Co., Ltd.	+8615821988213	info@longyupharma.com	China	2531	58
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	sales@chemdad.com	China	39916	58
Xi'an MC Biotech, Co., Ltd.	029-89275612 +8618991951683	mcbio_sales@163.com	China	2255	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	27644	58
Dayang Chem (Hangzhou) Co.,Ltd.	571-88938639 +8617705817739	info@dycnchem.com	CHINA	52861	58
Hangzhou Huarong Pharm Co., Ltd.	571-86758373 +8613588754946	sales@huarongpharm.com	CHINA	3149	58
LEAP CHEM CO., LTD.	+86-852-30606658	market18@leapchem.com	China	24738	58

Bromocriptine 관련 검색:

브로모시클로프로판 이소프로필브로마이드 3-브로모아니졸 프로파길브로마이드 브롬화알릴 브롬 BroMocriptine IMpurity E CHLOROPHOSPHONAZO III ALPHA-ERGOCRYPTINE Bromocriptine mesylate EP,(+)-BROMOCRIPTINE MESYLATE,BROMOCRIPTINE MESYLATE,(+)-BROMOCRIPTINE METHANESULFONATE,BROMOCRIPTINE METHANESULPHONATE Ergoline-8-carboxylic acid, 2-bromo-9,10-didehydro-6-methyl-, (8β)- BroMocriptine IMpurity F BroMocriptine-13C-d3 BroMocriptine IMpurity G Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (2'β,5'α,8α)- (9CI) 5'alpha(S)-sec-butyl-12'-hydroxy-2'-isopropylergotaman-3',6',18-trione (8S)-2-BroMo α-Ergocryptine Bromocriptine Impurity A (Mixture of Diastereomers)